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SM5-1 is a humanized mouse antibody which has a high binding speciﬁcity for a membrane protein of
about 230 kDa overexpressed in hepatocellular carcinoma (HCC), melanoma and breast cancer. In this
study, SM5-1-conjugated poly D, L (lactide-coglycolide) (PLA) PLA containing Cy7 (PLA-Cy7-SM5-1) was
prepared to study the targeting speciﬁcity of the bioconjugate to HCC-LM3-fLuc cell. Then, SM5-1-
conjugated PLA containing 5-ﬂuorouracil (5-FU) (PLA-5FU-SM5-1) and PLA containing 5-FU (PLA-5FU)
were prepared for treatment of subcutaneous HCC-LM3-fLuc tumor mice. The results showed that PLA-
5FU-SM5-1, PLA-5FU and 5-FU induced a 45.07%, 23.56% and 19.05% tumor growth inhibition rate,
respectively, on day 31 post-treatment as determined by bioluminescent intensity. In addition, in order
to evaluate the antitumor efﬁcacy of PLA-5FU-SM5-1, HCC-LM3-fLuc cells were injected into the liver to
establish the experimental orthotopic liver tumor models. The experiments showed that PLA-5FU-SM5-
1, PLA-5FU and 5-FU induced a 53.24%, 31.00%, and 18.11% tumor growth inhibition rate, respectively, on
day 31 post-treatment determined by the bioluminescent intensity of the abdomen in tumor-bearing
mice. Furthermore, we have calculated the three-dimensional location of the liver cancer in mice us-
ing a multilevel adaptive ﬁnite element algorithm based on bioluminescent intensity decay calibration.
The reconstruction results demonstrated that PLA-5FU-SM5-1 inhibited the tumor rapid progression,
which were consistent with the results of subcutaneous tumor mice experiments and in vitro cell
experiment results.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of
cancer-related deaths worldwide, with the incidence on the rise
[1e3]. Although many treatment options including liver transplant,
surgical resection, embolization, radio embolization and chemo-
therapy have been developed for patients with HCC, the ﬁve-year
survival rate is only approximately 26% in the United States and
has not been improved signiﬁcantly [3]. Population-based studies
show that the incidence rate is almost equal to the death rate,
indicating that most of the patients who develop HCC will die of it
in the near future [1].t
r Ltd. Open access under CC BY-NC-ND5-Fluorouracil (5-FU) is widely used in the treatment of a variety
of tumors. It can interferewith nucleoside metabolism and result in
DNA synthesis disorders and RNA dysfunction, leading to cytotox-
icity and cell death [4,5]. Over the past 20 years, increased under-
standing of the mechanism of action of 5-FU has led to the
development of many treatment strategies that improve its anti-
cancer activity [6e8]. However, the overall response rate for many
tumors to 5-FU alone remains only about 15% because of its drug
resistance [9]. Therefore, new strategies, which can improve the
antitumor efﬁcacy are urgently needed [10].
A variety of nanoparticles have been used to encapsulate 5-FU in
order to prolong the release time of the drug and improve accu-
mulation concentration in the body, thereby improving the anti-
tumor efﬁcacy [11]. Bozkir et al. have optimized the formulation of
poly D, L (lactide-coglycolide) (PLA) nanoparticles loaded with 5-FU
(5FU-NP) by a nano-precipitation-solvent displacement technique.
In their research, the in vitro release and antitumor activity of the
optimized formulation with maximum drug entrapment efﬁciency license.
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system was demonstrated to improve the cancer chemotherapy
efﬁcacy in vivo [12]. The 5-FU-colloidal gold complex (Au@5-FU)
was also prepared and observed to have appreciable antitumor
activity against breast cancer, colorectal cancer, leukemia, etc.,
which suggests that gold nanoparticles have the potential to be
used as effective carriers for 5-FU [13,14]. In addition, 5-FU-loaded
nanoparticles such as chitosan and polyaspartic acid sodium (CS-
PAsp) and poly(ethylene glycol)-poly(g-benzyl-L-glutamate)(PEG-
PBLG) demonstrated a sustained release of 5-FU [15e17]. As carriers
of antitumor drugs, PLA nanoparticles have many advantages
including being non-toxic, biodegradable, avoiding uptake by the
mononuclear phagocytes systems, etc. [18e21]. In addition, unlike
some micron vectors, PLA nanoparticles can easily reach the target
tissue and cells [22]. All of these studies suggest that 5-FU-PLA
nanoparticles have high potential as anticancer agents.
The treatment of HCC patients is particularly challenging
because of patient-speciﬁc, tumor-speciﬁc and liver-speciﬁc vari-
ables that impact our ability to treat patients safely and effectively
[3]. Targeted drug delivery is a promising approach and an attrac-
tive ﬁeld in tumor therapy. Many groups worldwide have done a lot
of research on targeted therapy using some common targeting
biomolecules such as anti-human epidermal growth factor receptor
2 (HER2) and Vascular Endothelial Growth Factor Receptor (VEGFR)
antibodies [23e27] and have made great progress. SM5-1 is a
member of a panel of humanized mouse monoclonal antibodies
(mAbs) generated by using a subtractive immunization protocol as
described previously [28]. SM5-1 can bind to a membrane protein
of about 230 kDa (p230), which is speciﬁcally expressed in HCC,
melanoma and breast cancer cells, making it a promising candidate
for cancer-targeted therapy and diagnosis [29e32]. In these ex-
periments, we found that the SM5-1 receptor was highly expressed
in HCC-LM3-fLuc cells, which indicated that the SM5-1 antibody
could be explored for targeted treatment of HCC (the method and
data are shown in supplemental data and Fig. S1).
Optical molecular imaging including bioluminescence imaging
and ﬂuorescence imaging have drawn more and more attention
due to their high sensitivity and low cost [33e36]. In recent years,
they have been more and more widely used in evaluating the ef-
ﬁcacy of antitumor drugs [37], mechanism of cancer metastasis
[38e40], image protein interactions [41e46], and so on. However,
two-dimensional molecular imaging cannot present accurate
three-dimensional information of inner optical sources, such as in
the liver, bone or lungs. Therefore, many reconstruction algorithms
have been proposed such as Tikhonov regularization [47], Bone-
type approximation bioluminescent tomography (BLT) method
[48], a trust region method in the adaptive ﬁnite element frame-
work [49], and the adaptive ﬁnite element method based on
bioluminescent intensity decay calibration [50]. With the devel-
opment of three-dimensional imaging technologies, these methods
have been initially applied in the detection of optical sources in the
liver and bone [50e52]. All of these studies indicated that the
three-dimensional reconstruction technology could provide a
powerful technique for further imaging applications.
In this paper, PLA nanoparticles loaded with 5-FU and modiﬁed
with SM5-1 (represented as PLA-5FU-SM5-1) were prepared and
evaluated in the treatment of liver tumors. In order to study the
antitumor efﬁcacy of PLA-5FU-SM5-1, in vitro cell proliferation
experiments and in vivo animal treatment experiments were car-
ried out using HCC-LM3-fLuc tumor models. We also reconstructed
three-dimensional location information of the inner tumor using
the adaptive ﬁnite elements method based on bioluminescence
intensity decay calibration. Finally, the immunohistochemistry
experiments were carried out to show the inﬂuence of the drug on
tumor proliferation, angiogenesis and apoptosis.2. Materials and methods
2.1. Materials and reagents
PLA (molecular weight of 80,000) was purchased from Shandong Institute of
Medical Instruments (Jinan, China). The standard 5-FU (batch No. PHR1227, purity
99%) was purchased from Sigma Company (Shanghai, China). CellTiter 96
AQUEOUS One Solution Cell Proliferation Assay (MTS, batch No. G358A) was pur-
chased from Promega Company (Madison, USA). Cy7 carboxylic acid (batch No.
45090) was purchased from Lumiprobe Company (Florida, USA). HCC-LM3-fLuc cells
and antibody SM5-1 were kindly provided by Professor Jian Zhao and Weizhu Qian
of Shanghai Second Military University respectively.
2.2. Preparation of 5-FU or Cy7 loaded PLA nanoparticles
Brieﬂy, aqueous solution of 5-FU (150 mL) was emulsiﬁed in 1.5 mL ethyl ace-
tate containing 40 mg PLA by sonication (15 W, 30 s). The resulting emulsion (w/o)
was emulsiﬁed again by sonication (15 W, 1 min) in an aqueous solution of 1%
polyvinyl alcohol to form the w/o/w double emulsion. The double emulsion was
then diluted into 30 mL of 0.3% polyvinyl alcohol and the system was maintained
under magnetic stirring for 8 h. The nanoparticles were collected by centrifugation
at 12,000 rpm for 30 min and washed three times with deionized water by
centrifugation at 12,000 rpm. Finally, the nanoparticle suspension was lyophilized
at a condenser temperature of 60 C and pressure of 5 mTorr to obtain the freeze-
dried powder. Blank nanoparticles were prepared in the same procedure describe
above. Cy7 encapsulated PLA nanoparticles were also prepared in the same pro-
cedure, the only difference was that Cy7 was dissolved into ethyl acetate rather
than deionized water.
2.3. Preparation of SM5-1-conjugated PLA containing 5-FU (or Cy7)
Coupling of humanized SM5-1 to the PLA nanoparticle was performed using 1-
ethyl-3-(3-dimethylamido-propyl) carbodiimide/N-hydroxysuccinimide (EDC/NHS)
as the coupling agents. PLA nanoparticle solution (45 mg) containing 5-FU (5FU e
PLA) was dissolved in 9 mL of 10 mmol/L NaH2PO4 (pH 6.3). This solution was
activated with a mixture of NHS (0.1 mL, 50 mg/mL) and EDC (0.1 mL, 50 mg/mL) for
30 min, then antibody SM5-1 dissolved in PBS buffer (2 mL, 3.1 mg/mL, pH 7.4) was
added and the reaction lasted for 4 h at room temperature. The resulting product
PLA-5FU-SM5-1 was puriﬁed by washing it three times with deionized water to
remove unbound antibody and was then lyophilized. Similarly, PLA-Cy7-SM5-1 was
prepared with the same procedure as above.
2.4. Determination of 5-FU content and encapsulation efﬁciency
SM5-1 modiﬁed PLA-5FU was chosen randomly, weighed precisely with a bal-
ance and dissolved in 2 mL dichloromethane. Hydrochloric acid (HCl, 5 mL of
0.1 mol/L) was administered 3 times to extract 5-FU entirely by agitation and
centrifugation (1400 g, 15 min  3). The supernatant was collected and measured
by a UVeVis spectrophotometer. Repeated determinations were taken 6 times
(n ¼ 6). The encapsulation efﬁciency and loading content of 5-FU in PLA was
calculated according to the following equation:
Encapsulation efficiencyð%Þ ¼ weight of drug in nanoparticles
weight of the feeding drug
 100% (1)
Drug loading contentð%Þ ¼ weight of drug in nanoparticles
weight of nanoparticles
 100% (2)
2.5. Morphological observation
The morphology of PLA-5FU-SM5-1, PLA-5FU and blank PLA nanoparticles was
observed by scanning electron microscopy (SEM, Hitachi S-4300; Hitachi, Tokyo,
Japan) with accelerating voltage of 15 KV. Transmission electron microscopic (TEM)
images of blank PLA-5FU-SM5-1 and PLA-5FU were acquired by a Tecnai Spirit
Microscope with a charge coupled device (CCD) camera operated at 80 KV.
2.6. In vitro release studies
The in vitro release of 5-FU was analyzed using a dialysis method [53]. Before
drug release from the prepared nanoparticles, PLA-5FU-SM5-1, PLA-5FU and 5-FU
were freeze-dried and the powders were re-dissolved in PBS (pH ¼ 7.4) at a ﬁnal
concentration of 2 mg/mL. Each (1 mL) of the three samples at a concentration of
2 mg/mL was placed in a dialysis bag, which was immersed in a vial containing
20mL of 10mM PBS (pH¼ 7.4) and incubatedwhile stirring at 37 C for 120 h. A 1mL
aliquot of the release medium was withdrawn from the vial and replaced with an
equal volume of fresh PBS at predetermined times. The 5-FU released from the
nanoparticles was analyzed spectrophotometrically, and the solution was deter-
mined by the absorption peak intensity at 267 nm. The results were reported as
mean  SD (n ¼ 5).
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HCC-LM3-fLuc human hepatocellular carcinoma cells were grown in Dulbecco’s
Modiﬁed Eagle’s Medium supplemented with 10% fetal bovine serum (FBS) in a
humidiﬁed incubator at 37 C in a 5% CO2 atmosphere.
2.8. In vitro cell proliferation assay
Hepatocellular carcinomaHCC-LM3-fLuc cells were plated in four sections of 96-
well plates (1 104 per well) and incubated overnight. The cells were then exposed
to a series of concentrations of 5-FU or PLA-5FU or PLA-5FU-SM5-1 for 3 days. For
three sections of the 96-well plate, cell viability was measured using a CellTiter 96
nonradioactive cell proliferation assay kit (MTS, Promega). Brieﬂy, a 20 mL MTS so-
lution was added to each well. After incubation for 2 h at 37 C, the absorbance was
measured at 570 nm using a BioTek Synergy HT Universal Microplate Reader. For
another 96-well plate, we added PLA-5FU-SM5-1, and 20 mL of luciferin were added
to each well. After incubation for 3 min at 37 C, the bioluminescent images (BLI)
were acquired using the in-house bioluminescence imaging system developed by
ourselves [47,50]. The parameters of CCD (Princeton Instruments PIXIS 1024BR,
Roper Scientiﬁc, USA) were set at exposure time ¼ 2 min, f-number ¼ 1.2,
binning ¼ 4, controller gain ¼ 3, rate ¼ 1 MHz, resolution ¼ 16 bits, and
readout ¼ low noise. The experiments were carried out in a completely dark envi-
ronment in order to avoid the inﬂuence of outside light.
2.9. Toxicity studies
Liver immortalized cells LO2 were kindly provided by Dr. Xin Tong and were
plated in 96-well plates (1 104 per well) overnight. The cells were then exposed to
a series of concentrations of 5-FU or PLA-5FU or PLA-5FU-SM5-1 for 3 days. The
samples were analyzed using the same procedure as described above in the section
of “In vitro cell proliferation assay”.
2.10. Animal models
Female BALB/c nude mice (4 weeks of age) were purchased from the Depart-
ment of Experimental Animals, Peking University Health Science Center. All animal
experiments were performed in accordance with the guidelines of the Institutional
Animal Care and Use Committee at Peking University.
2.11. In vivo antitumor study based on subcutaneous live tumor mice
The HCC-LM3-fLuc tumor model was established by subcutaneous injection of
2  106 HCC-LM3-fLuc tumor cells into the right upper ﬂanks of BALB/c nude mice.
Antitumor activities of 5-FU, PLA-5FU and PLA-5FU-SM5-1 were determined in
mice bearing the HCCs. The mice were divided into four groups and subjected to
antitumor treatment when the tumor volume reached z100 mm3 (about 8 days
after inoculation). Four groups of HCC-LM3 tumor-bearing mice (n ¼ 5 per group)
were treated with saline, 5-FU, PLA-5FU-SM5-1, or PLA-5FU (10 mg 5-FU per ki-
logram for four consecutive days) respectively. The tumor volume was estimated,
assuming the tumors were ellipsoid, using the formula volume ¼ 4p/3 (1/2
length  1/2 width  1/2 height). Tumor size was measured on day 0, 3, 7, 11, 15,
19, 23, 27, and 31 after treatment. In addition, we acquired the bioluminescent
images of the tumor-bearing mice and calculated the bioluminescent intensity to
evaluate antitumor efﬁcacy on day 0, 3, 7, 11, 15, 19, 23, 27, and 31 respectively. The
image acquisition and bioluminescent intensity calculation method were described
in our previous work [37]. During the bioluminescent image acquisition, the pa-
rameters of the CCD were set the same as those of the “In vitro cell proliferation
assay” except the binning ¼ 1, and the experiments were carried out in a
completely dark environment.
2.12. In vivo antitumor study in mice bearing the orthotopic HCC model
The orthotopic HCC mouse model was established by injecting 2  106 HCC-
LM3-fLuc tumor cells into the liver of BALB/c nude mice. The mice were divided into
four groups and subjected to antitumor treatment on the 7th day after inoculation.
Four groups of orthotopic HCC tumor-bearing mice (n ¼ 3 per group) were treated
with saline, 5FU, PLA-5FU, or PLA-5FU-SM5-1 (10 mg 5-FU per kilogram on four
consecutive days) respectively. The antitumor efﬁcacy was evaluated on day 0, 6, 11,
16, 21, 26, and 31 by acquiring the bioluminescent images of the abdomen of the
tumor-bearing mice and calculated the bioluminescent intensity. Each mouse was
fasted to reduce the inﬂuence of autoﬂuorescence for 4 h before in vivo BLI. The
image was acquired at 8 min after intraperitoneal injection with 200 mL D-luciferin
(Biotium, Inc., USA) and the parameters of CCD were set as the same as the above
section. In addition, we acquired four bioluminescent images at 0 , 90 , 180 , and
270 from four mice (one mouse per group) for reconstruction of the three-
dimensional bioluminescent images using the same parameters as the BLI
acquisition.
2.13. Three-dimensional reconstruction of the inner source using the adaptive
elements methods based on bioluminescent intensity decay calibration
Since the experiment was carried out in a totally dark environment, the prop-
agation of bioluminescent photons in the mice tissues could be represented by thesteady-state diffusion equation in BLT [54,55]. In our paper, the adaptive ﬁnite
element method (FEM) based on bioluminescent intensity decay calibration was
chosen to reconstruct the inner source of the mice [50]. Based on FEM, the diffusion
equation could be ﬁnally transformed to:
ASP ¼ Fm (3)
The three-dimensional bioluminescent sources of the four mice from the four
groups were reconstructed using the above method. In order to improve the
reconstruction accuracy, the mice were segmented into six major organs, including
muscle, lungs, liver, spleen, heart, and bone for using the heterogeneous parameters
of different tissues. The segmented CT volume data was discretized into 3246 points
and 15384 tetrahedrons. To induce the ill-posedness of reconstruction, a permissible
source region strategy was adopted and the permissible source region (PS) was
set to:
PS ¼ fðx; y; zÞj12 < x < 26; 10 < y < 28; 26 < z < 42; ðx; y; zÞ˛Ug (4)
In order to evaluate the antitumor efﬁcacy, the tumor inhibition rate determined
by the bioluminescent intensity could be calculated according to the following
equation:
Sd  Sc
Sc
 100% (5)
where Sd is the bioluminescent intensity of the PLA-5FU-SM5-1, PLA-5FU, 5-FU
treated group, Sc is the bioluminescent intensity of the control group.
Meanwhile, after reconstruction, we could calculate the virtual volume (Vvirtual)
of the liver tumor located in the liver, and calculated the total volume (Vtotal) of the
reconstructed tetrahedrons as well [50]. The volume of every tetrahedron was
calculated by the following equation:
1
6

x1 y1 z1 1
x2 y2 z2 1
x3 y3 z3 1
x4 y4 z4 1

(6)
where (x1, y1, z1), (x2, y2, z2), (x3, y3, z3), and (x4, y4, z4) are four vertices of the tet-
rahedron. Then, the reconstruction accuracy determined by the location was
calculated by:
RA ¼
XM
i¼ 1
V ivirtual=
XN
j¼1
V jtotal; (7)
where M is the number of reconstructed tetrahedrons that are located in the liver
and N is the total number of reconstructed tetrahedrons.
2.14. Immunohistochemical examination and analysis
For a histology evaluation of tumor proliferation, angiogenesis and apoptosis,
PBS-treated (n ¼ 2), PLA-5FU-SM5-1-treated (n ¼ 2), PLA-5FU (n ¼ 2) and 5-FU-
treated (n ¼ 2) tumors (16 days post-treatment) were excised, ﬁxed in formalin,
embedded in parafﬁn and cut into 3.0 mm sections for immunohistochemical
staining. For tumor proliferation, a set of sections was immunostained with puriﬁed
anti-MKI67 mouse monoclonal antibody (KI67, Cat. NO. TA500265, Zhongshan Jin-
qiao Bio-company, Beijing, China) [56]. In situ apoptosis assay was carried out with
the Fluorescein FragEL DNA fragmentation Detection Kit (Calbiochem, San Diego,
CA). Formalin-ﬁxed parafﬁn sections were deparafﬁnized and incubated with ter-
minal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-mediated
deoxyuridine triphosphate nick-end labeling (TUNEL, QIA39) reaction mixture
[57,58]. Apoptotic HCC-LM3-fLuc cells labeled with ﬂuorescein isothiocyanate-dUTP
were observed under the ﬂuorescence microscope (Leica DFC450C). Five ﬁelds of
each section (three sections of every group for the immunostain) were chosen
randomly for counting the apoptosis cells and proliferation cells using the methods
described in Refs. [57,58]. Tumor micro-vessel density (MVD) was quantiﬁed using
sections immunostained with CD31 (BioLegend, San Diego, CA) by two investigators
independently and in a blinded manner according to the method described previ-
ously [59]. Thewhole sectionwas scanned at low power (40) to determine the best
ﬁelds for counting. Counting was performed on ﬁve separate ﬁelds of each section
(three sections per mouse) chosen randomly at 200 magniﬁcation. Each stained
endothelial cell or cell cluster was counted as onemicro-vessel. If two ormore CD31-
positive foci were continuous in space, this was counted as one micro-vessel. The
average vessel counted from these ﬁelds in the three sections was used for MVD
scoring.
2.15. Statistical analysis
Quantitative data were expressed as mean  SD. Means were compared using
one-way analysis of variance (ANOVA) and a Student t-test, and p values< 0.05 were
considered statistically signiﬁcant.
Fig. 1. Schematic illustration of the fabrication process of PLA, PLA-5FU and PLA-5FU-SM5-1.
Table 1
Properties of PLA-based drug delivery systems.
Sample Drug loading content (%) Encapsulation efﬁciency (%)
PLA-5FU 9.89  0.57 8.98  0.89
PLA-5FU-SM5-1 9.87  0.58 8.97  0.94
Fig. 2. SEM images of PLA (A), PLA-5FU (B) and PLA-5FU-SM5-1 (C)
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3.1. Nanoparticle preparation and characterizations
Nanoparticles PLA-5FU and PLA-5FU-SM5-1 were obtained us-
ing the double nipple solvent evaporation method. The schematic
illustration of the fabrication process of nanoparticles is shown in
Fig. 1. It is known that PLA-based drug delivery systems usually; TEM images of PLA (D), PLA-5FU (E), and PLA-5FU-SM5-1 (F).
Fig. 3. In vitro release of 5-FU from PLA-5FU-SM5-1 (C) and vesicle-free (-) in 120 h
and 5-FU release from vesicle-free in 1 h (;) shown in the inserted ﬁgure.
X. Ma et al. / Biomaterials 35 (2014) 2878e28892882have a relatively low encapsulation efﬁciency and drug loading
(<5%) for water-soluble drugs with low molecular weights.
Compared to other studies [60e62], our systems and methods
showed better performance with 9.87  0.58% (n ¼ 3) encapsula-
tion efﬁciency and 8.97  0.94% drug loading, which is mainly due
to the addition of excess 5-FU (shown in Table 1).
The obtained nanoparticles PLA-5FU and PLA-5FU-SM5-1 were
examined by TEM and SEM. As shown in Fig. 2 A, B and C, the
nanoparticles PLA, PLA-5FU and PLA-5FU-SM5-1 were spherical,
and the vesicular size measured by SEM was consistent with theFig. 4. (A) Anti-proliferative effects of 5-FU, PLA-5FU, and PLA-5FU-SM5-1 on HCC-LM3 cell
viability of cells was examined after 72 h exposure to different vesicles (black stands for 5-F
Data shown as means  SD (n ¼ 5). (C) Bioluminescent image of anti-proliferative effects of P
kidney (c) and spleen (d) stained with H&E after PBS, 5-FU, PLA-5FU and PLA-5FU-SM5-1 tre
referred to the web version of this article.)results measured by TEM. In addition, the nanospheres could
shrink rapidly in the light during TEM scanning which are shown in
Fig. 2D, E, and F. Both SEM and TEM results showed that the particle
size was uniform and around 100 nm, which contributed to the
characteristics of the absorption, metabolism and excretion of
drugs in small animal tumor models.
3.2. In vitro drug release studies
The release proﬁles of 5-FU from the nanospheres are presented
in Fig. 3. The release of free 5-FU from a dialysis bag (denoted as
nanosphere-free) was also examined. Without nanospheres, about
84.66% of 5-FU was released from the dialysis bag in 1 h, suggesting
that the use of a dialysis bag would not affect the analysis of 5-FU
release from PLA over a long timescale, e.g. several tens of hours.
As shown in Fig. 3, PLA released 12.95% of the encapsulated 5-FU in
1 h, and 46.58% and 83.40% of the encapsulated 5-FU in 26 h and
74 h respectively. As a result, a total of 90.00% of 5-FU was released
fromnanospheres in 98 h. The ﬁgure shows that 5-FU released from
PLA-5FU-SM5-1 consisted of two phases: an initial burst release (in
1 h) and subsequent sustained release phase. The release proﬁles of
PLA-5FU were consistent with those of PLA-5FU-SM5-1.
3.3. In vitro proliferation assay and toxicity studies
Fig. 4 (A and B) shows the activity of various drugs tested on
HCC-LM3-fLuc and LO2 cells lines. Fig. 4C displays the biolumi-
nescent image after different drug concentrations of PLA-5FU-SM5-
1 were added to HCC-LM3-fLuc cells and incubated for 72 h. It
clearly indicates (Fig. 4A) that all three drugs inhibited HCC-LM3-
fLuc cell proliferation in a dose-dependent fashion, which was
consistent with the results of bioluminescent imaging (Fig. 4C).s. (B) Anti-proliferative effects of 5-FU, PLA-5FU, and PLA-5FU-SM5-1 on LO2 cells. The
U; red stands for PLA-5FU; blue stands for PLA-5FU-SM5-1) at different concentrations.
LA-5FU-SM5-1 on HCC-LM3 cells (n ¼ 3). (D) The slide sections of the liver (a), heart (b),
atment. (For interpretation of the references to color in this ﬁgure legend, the reader is
X. Ma et al. / Biomaterials 35 (2014) 2878e2889 2883Moreover, at the same drug concentration, PLA-5FU-SM5-1 dis-
played higher cytotoxicity against HCC-LM3-fLuc cells as compared
with PLA-5FU and 5-FU. Taking a drug concentration of 0.05 mg/mL
for example, PLA-5FU-SM5-1 induced 56.4 3.47% cell death versus
PLA-5FU which induced 51.1  4.32% cell death and 5-FU induced
49.8  4.87% cell death. The experiments indicated that the SM5-1
antibody may lead to a higher and longer accumulation of 5-FU and
thereby induce stronger cytotoxicity. Interestingly, the toxicity
study of the three drugs based on LO2 cells showed that 5-FU
induced more LO2 cell death in contrast to PLA-5FU and PLA-
5FU-SM5-1 at the same concentration (Fig. 4B). This probably
means that 5-FU has certain side effects.
In order to evaluate the toxicity of PLA-5FU-SM5-1, PLA-5FU and
5-FU in vivo, organs such as the heart, liver, spleen and kidneys of
the mice from the four treatment groups were obtained and cut on
the 16th day post-treatment, and the sections of different organs
were stained with H&E. The results obtained from the ﬂuorescence
microscope images showed that the toxicity of the three drugs on
the organs was not obvious except for some degree of liver damage
[63,64] (Fig. 4D).Fig. 5. (A) HCC-LM3-fLuc tumor sizes of the nude mice that underwent PLA-5FU-SM5-1, PLA
expressed as a function (mean  SD, n ¼ 5 per group). (B) The quantiﬁed bioluminescent in
PLA-5FU, 5-FU and saline treatment. (C) The mice weight of the four groups over time (n
quantitative bioluminescent intensity of the four groups on the 31st day post-treatment (p3.4. In vivo antitumor study based on a subcutaneous liver tumor
To evaluate antitumor activities of different drugs, mice were
implanted subcutaneously with HCC-LM3-fLuc cells, and a therapy
study was initiated when the tumor size reached about 100 mm3
through a tail vein injection of PLA-5FU-SM5-1, PLA-5FU, 5-FU or
saline. Tumor-bearing mice were treated with four doses given
sequentially on day 0, 1, 2, and 3. The tumor sizes of nude mice
were then measured with calipers. As shown in Figs. 5 and 6, the
tumor sizes still increased in all of the four treatment groups. But
interestingly, on day 7, the tumor sizes in the 5-FU treatment
group were signiﬁcantly smaller than those in the PLA-5FU and
PLA-5FU-SM5-1 group, and the inhibition rates were
21.71  3.67%, 7.74  2.97%, and 18.84  3.12% respectively. Af-
terward, the tumor sizes in the PLA-5FU-SM5-1 treated group
were signiﬁcantly smaller than those in the other three groups.
Finally, on day 31, the inhibition rates of PLA-5FU-SM5-1, PLA-5FU
and 5FU treated group were 30.69  2.96, 12.54  3.45 and
9.15  3.45 respectively.
The baseline BLI signal was also determined on the day before
the ﬁrst drug administration, and then BLI was performed on day 0,-5FU, 5-FU and saline treatment. Volumes of tumors in each group were measured and
tensity of the HCC-LM3-fLuc tumors in the nude mice that underwent PLA-5FU-SM5-1,
¼ 5 per group). The drug administration intervals are indicated by arrows. (D) The
< 0.01, Mean  SD, n ¼ 5).
Table 2
Inhibition rates of PLA-5FU-SM5-1, PLA-5FU, and 5-FU on HCC-LM3-fLuc tumors
post-treatment determined by tumor volume.
Day after treatment PLA-5FU-SM5-1 PLA-5FU 5-FU
7 18.84  3.12** 7.74  2.97 21.71  3.67
11 34.56  4.21# 24.47  3.59 16.97  4.12
15 25.32  3.47## 20.58  2.78 7.42  2.89
19 28.40  4.01*,# 17.48  4.43 13.82  3.75
23 30.01  3.94*,## 21.77  3.12 13.10  3.45
27 29.65  4.02**,## 15.23  3.87 12.58  4.23
31 30.69  2.96**,## 12.54  3.45 9.15  3.87
* Indicates p < 0.05, ** indicates p < 0.01 (PLA-5FU-SM5-1 treated group and PLA-
5FU treated group); # indicates p < 0.05, ## indicates p < 0.01 (PLA-5FU-SM5-1
treated group and 5-FU treated group).
X. Ma et al. / Biomaterials 35 (2014) 2878e288928843, 7, 11, 15, 19, 23, 27, and 31 respectively to monitor the progression
of the HCC-LM3-fLuc tumor burden. The presence of HCC-LM3-fLuc
cells in the right ﬂank could be clearly detected upon the intra-
peritoneal injection with 200 mL D-Luciferin. For the saline group,
sustained tumor growth was observed (Fig. 5A and B, Fig. 6). As
expected, the treatment with 5-FU, PLA-5FU, and PLA-5FU-SM5-1
clearly inhibited all tumor growth in vivo, although they were not
able to completely ablate tumor progression. As determined by BLI
(Fig. 5B and Table 3), it was found that the bioluminescent intensity
of the 5-FU treatment group was the weakest among the three
treatment groups, and PLA-5FU-SM5-1, PLA-5FU, and 5-FU induced
a 21.88  4.15%, 11.42  4.32% and 40.44  2.99% tumor growth
inhibition rate on day 7 post-treatment respectively. Afterward, the
bioluminescent intensity of the PLA-5FU-SM5-1 treatment group
was obviously much weaker than that of the other three groups.
From the data shown in Fig. 5 A, B and Tables 2 and 3, the antitumor
efﬁcacy determined by BLI was found to be consistent with that
determined by tumor size measurement. Moreover, Fig. 5D
revealed that the bioluminescent intensity of the PLA-5FU-SM5-1
treated group was much lower than that of the other two groups.
The inhibition rates of the PLA-5FU-SM5-1, PLA-5FU, and 5-FU
treatment groups were 45.07  2.93%, 23.56  3.59% andFig. 6. Serial bioluminescent images of the HCC-LM3-fLuc tumor-bearing nude mice t19.05  3.04% respectively on the 31st day after the ﬁrst dose
(p < 0.01).
Throughout the antitumor study, the weights of PLA-5FU-SM5-
1, PLA-5FU, 5-FU and saline-treated mice were monitored (Fig. 5C).
Although there was a slight loss of body weight from day 3
compared to the saline control group, none of the animals in the
three drug-treated groups lost >20% of their original weight.hat underwent PLA-5FU-SM5-1 (A), PLA-5FU (B), 5-FU(C) or saline (D) treatment.
Table 3
Inhibition rate of PLA-5FU-SM5-1, PLA-5FU, and 5-FU on HCC-LM3-fLuc tumor post-
treatment determined by bioluminescent intensity (BLI).
Day after treatment PLA-5FU-SM5-1 PLA-5FU 5-FU
7 21.88  4.15*,## 11.42  4.32 40.44  2.99
11 62.15  3.67**,## 24.46  3.87 20.77  3.68
15 57.85  4.03**,## 25.70  3.91 10.76  4.13
19 40.81  3.98**,## 25.07  3.64 16.57  3.44
23 46.86  3.95**,## 23.50  3.07 20.15  3.81
27 49.79  3.46**,## 25.83  4.14 21.19  3.21
31 45.07  2.93**,## 23.56  3.59 19.05  3.04
* Indicates p < 0.05, ** indicates p < 0.01 (PLA-5FU-SM5-1 treated group and PLA-
5FU treated group); # indicates p < 0.05, ## indicates p < 0.01 (PLA-5FU-SM5-1
treated group and 5-FU treated group).
X. Ma et al. / Biomaterials 35 (2014) 2878e2889 28853.5. In vivo antitumor study based on an orthotopic liver tumor
To evaluate antitumor activities, mice were also implanted in
the liver with HCC-LM3-fLuc cells and intravenous therapy wasFig. 7. (A) Bioluminescent images of orthotopic liver tumor mice from four groups on the 3
liver tumors that underwent PLA-5FU-SM5-1, PLA-5FU, 5-FU, and saline treatment. (C) The
treatment (p < 0.01, mean  SD, n ¼ 3).initiated on day 7 using PLA-5FU-SM5-1, PLA-5FU, 5-FU and saline.
Animals were treated with four doses given on days 0, 1, 2 and 3.
The bioluminescent images of the abdomen of the tumor-bearing
mice were acquired on days 0, 6, 11, 16, 21, 26 and 31 and the
bioluminescent intensity of eachmice could be calculated using the
software Windows Molecular Imaging System (WINMI) developed
by ourselves [37]. For the control group, BLI signals of the mice
increased rapidly and became signiﬁcantly different from the other
three drug-treated groups from day 6 post-treatment (Fig. 7). As
expected, 5-FU clearly inhibited tumor growth in vivo on the 6th
day post-treatment, although tumor growth inmice from the 5-FU-
treated group exceeded that of mice from the PLA-5FU-SM5-1 and
PLA-5FU treated groups subsequently. Compared with the saline
treated group, the tumor inhibition rates of PLA-5FU-SM5-1, PLA-
5FU, and 5-FU were 53.24 3.24%, 31.00  3.65% and 18.11  3.89%
respectively as determined by Equation (5) according to the
bioluminescent intensity of the abdomen of tumor-bearing mice
derived from WINMI (P values are all < 0.05; Fig. 7C). Moreover,
it was also found that PLA-5FU-SM5-1 could effectively inhibit1st day post-treatment; (B) The quantiﬁed bioluminescent intensity of the orthotopic
quantiﬁed bioluminescent intensity of tumors from the four groups on day 31 post-
Fig. 8. Reconstruction results of a PLA-5FU-SM5-1 (A) or saline (B) treated mouse using the adaptive ﬁnite elements method based on bioluminescent intensity calibration. Four
sub-ﬁgures are the reconstructed bioluminescence distribution at different angles based on the heterogeneous mouse. The dark blue (half-moon-shaped) area is the liver.(For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(P < 0.05; Fig. 7B).
In order to show the three-dimensional information of the
orthotopic liver tumor, the BLT method was used to reconstruct the
inner bioluminescence source. During reconstruction, the
threshold was set at 0.5 and the regularization was set to i  1011
(i ¼ 1, 2, 3, 4, 5, 6, 7, 8, 9). The reconstruction results of PLA-5FU-
SM5-1 and the control group based on heterogeneous mice are
shown in Fig. 8. After reconstruction, we calculated the virtual
volume (Vvirtual) of the liver tumor located in the liver, and calcu-
lated the total volume (Vtotal) of the reconstructed tetrahedrons as
well [50]. The volume of every tetrahedron was calculated ac-
cording to Equation (6) and the reconstruction accuracy was
calculated by Equation (7).
The average reconstruction accuracy of the nine reconstruction
results of every mouse was calculated and is shown in Table 4. The
reconstructed elements (the elements where the bioluminescent
intensity was greater than 70% of the maximum bioluminescent
intensity were considered to be the true tumor) of PLA-5FU-SM5-1
treated mice were far fewer than those of PLA-5FU, 5-FU and saline
treated group mice. According to Equations (6) and (7), the average
reconstruction accuracy of the four groups was greater than 80%
which demonstrated that the reconstruction results were credible
for evaluating the antitumor efﬁcacy based on orthotopic liver tu-
mor mice models. The reconstruction ﬁgure (Fig. 8) demonstrates
that PLA-5FU-SM5-1 showed higher antitumor efﬁcacy as
compared with the control saline treatment group. The quantita-
tive reconstruction results (Table 4) showed that PLA-5FU-SM5-1,
PLA-5FU, and 5-FU improved the tumor inhibition rates by
48.82  4.07%, 28.89  3.59% and 14.44  4.32% respectively as
compared with the saline treated group, which were consistent
with the aforementioned results.Table 4
Reconstruction results of the four groups using the ﬁnite element method based on biol
Group Reconstruction elements (>70%) Bioluminescent intensity
Control 139  18 6.37  0.97
5-FU 107  19 5.45  0.86
PLA-5FU 96  16 4.53  0.73
PLA-5FU-SM5-1 89  15 3.26  0.643.6. The effect of PLA-5FU-SM5-1 on tumor angiogenesis, apoptosis
and proliferation
Data above suggested that PLA-5FU-SM5-1 could inhibit tumor
proliferation and induce tumor cell apoptosis. To more rigorously
demonstrate this result, HCC-LM3-fLuc xenografted tumor tissues
from saline, 5-FU, PLA-5FU and PLA-5FU-SM5-1 treated mice were
stained using a TUNEL assay and KI67 assay and then observedwith
the ﬂuorescence microscope (shown in Fig. 9). From Fig. 9AeD, the
number of apoptotic nuclei, seen as a green color under ﬂuores-
cence microscopy, was greatly decreased in PLA-5FU, 5-FU or saline
treated xenografts than those in PLA-5FU-SM5-1 treated xeno-
grafts. Fig. 9EeH shows that the inhibitory effects of PLA-5FU-SM5-
1 on tumor growth were consistent with the results of the
apoptosis study revealed by the TUNEL assay. The quantitative re-
sults (Fig. 9M and N) showed that the antitumor efﬁcacy of PLA-
5FU-SM5-1 increased about 50% than that of 5-FU. Angiogenesis
is a prerequisite for advanced tumor growth and we counted the
number of vessels per ﬁeld to evaluate the anti-angiogenesis efﬁ-
cacy of the drugs. The results showed that PLA-5FU-SM5-1 could
down-regulate tumor angiogenesis as compared with PLA-5FU, 5-
FU and saline. Thus, all these data demonstrated PLA-5FU-SM5-1
could improve the antitumor efﬁcacy as compared with PLA-5FU
and 5-FU because of the targeting characteristics of SM5-1.
4. Discussion
Hepatocellular carcinoma HCC-LM3 is a subtype of liver cancer
found in Asia with a high incidence and high death rate [58,65].
5-FU is a common antitumor drug, which can be used in the
treatment of a wide range of cancers, including colorectal, breast
cancer and cancers of the digestive tract, but it has been rarelyuminescent intensity calibration.
(106photons/s) Average reconstruction accuracy Reconstruction times
83.56  6.75% 9
84.7  7.86% 9
83.98  6.12% 9
85.12  5.89% 9
Fig. 9. Immunohistochemistry analysis of tumor cell apoptosis, cell proliferation and angiogenesis 15 days post-treatment after PBS (A, E, I), 5FU (B, F, J), PLA-5FU(C, G, K), and PLA-
5FU-SM5-1 (D, H, L) treatment. Arrows indicate the apoptotic cells, proliferative cells and CD31-positive cells. M, N, and P are the quantitative results of cell apoptosis, proliferation
and angiogenesis respectively.
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tumor inhibition rate for advanced colorectal cancer is less than
20%, which largely restricts its clinical application and treatment
for other tumors [66]. We thus prepared SM5-1-conjugated PLA
nanoparticles loaded with 5-FU and apply it in the treatment of
HCC-LM3 cancer. Our studies demonstrate that PLA-5FU-SM5-1
nanoparticles improved the antitumor efﬁcacy by more than 20%
based on subcutaneous tumor models as compared with 5-FU and
PLA-5FU. Furthermore, we found that the tumor inhibition ratewas
increased by more than 30% based on the orthotopic liver tumor
mouse models. Then, the qualitative and quantitative results of
targeted experiments showed that PLA-Cy7-SM5-1 had bettertargeting characteristics for orthotopic liver cancer than subcu-
taneous liver tumors (shown in supplemental data Fig. S2 and
Table S2).
Targeted drug delivery research is an attractive ﬁeld in tumor
therapy. Research activity aimed towards achieving speciﬁc and
targeted delivery of antitumor agents has expanded tremendously
in the last several years with new avenues of directing drugs to
tumors as well as new encapsulation methods of drugs [11].
Research efforts to improve chemotherapy over the past few years
have led to an improvement in patient survival. However, there is a
great deal more we can do to treat and perhaps prevent cancer
metastasis by treating it as early as possible. PLA-5FU-SM5-1, as
X. Ma et al. / Biomaterials 35 (2014) 2878e28892888demonstrated in this paper, has a prolonged circulation with 80%
release of 5-FU in 72 h and it could target the tumor speciﬁcally,
thereby increasing its antitumor activity while reducing its toxic
side effects. This research proposed a new direction for the wide
application of 5-FU.
In short, the effectiveness of the treatment was directly related
to the ability to target and kill cancer cells while affecting as few
healthy cells as possible. Then, how to evaluate this effectiveness
was an important question too. This will require the development
of superior detection methods and imaging technology [67e69].
Molecular imaging, especially optical molecular imaging, has been
widely used in biological and medical research over a few years of
development. However, three-dimensional bioluminescence
reconstruction technologies were rarely used in cancer research
and drug evaluation because of the complexity and ill-posedness of
the algorithm. In this study, we obtained similar results with the
traditional drug evaluation method using the adaptive ﬁnite
element reconstruction method based on bioluminescent intensity
decay calibration. This research clearly demonstrated the feasibility
and superiority of this approach.
Future studies might focus on several directions: ﬁrst of all, new
therapeutic targets such as blood vessels fueling tumor growth
could be developed and targeted therapeutics would be more
widely used in tumor treatment; second, a set of key marker genes
could be deﬁned and used for the prospective evaluation of tumor
response to 5-FU and other chemotherapeutic agents for further
research; third, more rapid and convenient three-dimensional
reconstruction methods should be developed to make them more
widely used in drug evaluation, or even used in tumor metastasis
detection; and ﬁnally, there is an urgent need for developing a
multimodality molecular imaging system and calculation platform
to facilitate our research in biomedical areas and pharmaceuticals
development.
5. Conclusion
In this study, we prepared 5-FU-loaded PLA nanoparticles con-
jugated with SM5-1 (PLA-5FU-SM5-1), which exhibited favorable
characteristics, including sustained drug release in an actively tar-
geted tumor. In vitro, PLA-5FU-SM5-1 induced 56.4% cell death
versus PLA-5FU, which induced 51.1% cell death and 5-FU induced
49.8% cell death. In vivo, PLA-5FU-SM5-1 nanoparticles showed
good antitumor activity against HCC-LM3-fLuc cancer xenografts
including subcutaneous tumors and orthotopic liver tumors.
Meanwhile, the three-dimensional bioluminescent sources from
the four treatment groups were reconstructed using the adaptive
ﬁnite elements method based on bioluminescent intensity decay
calibration. The statistical results of 9 reconstructions demon-
strated that the tumor inhibition rate of PLA-5FU-SM5-1 was
48.80% which was consistent with the two dimensional BLI results.
In addition, the in vivo target experiments conﬁrmed and explained
the results of the in vivo antitumor experiments. Taken together,
our results indicated that a PLA nanoparticle delivery and antibody
SM5-1 target system for 5-FU could effectively improve the ther-
apeutic index of 5-FU and the three-dimensional reconstruction
technology can provide us with a feasible method for antitumor
evaluation based on inner tumor mice models.
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